0001209191-17-047716.txt : 20170804 0001209191-17-047716.hdr.sgml : 20170804 20170804164206 ACCESSION NUMBER: 0001209191-17-047716 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170802 FILED AS OF DATE: 20170804 DATE AS OF CHANGE: 20170804 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chodakewitz Jeffrey CENTRAL INDEX KEY: 0001610876 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 171009147 MAIL ADDRESS: STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC. STREET 2: 480 ARSENAL ST., SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-08-02 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001610876 Chodakewitz Jeffrey C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP GMDA, CMO Common Stock 2017-08-02 4 M 0 1796 91.05 A 116220 D Common Stock 2017-08-02 4 S 0 500 152.50 D 115720 D Common Stock 2017-08-02 4 S 0 600 153.93 D 115120 D Common Stock 2017-08-02 4 S 0 400 154.89 D 114720 D Common Stock 2017-08-02 4 S 0 296 156.24 D 114424 D Common Stock 2017-08-03 4 M 0 3594 109.14 A 118018 D Common Stock 2017-08-03 4 S 0 600 153.29 D 117418 D Common Stock 2017-08-03 4 S 0 2494 154.21 D 114924 D Common Stock 2017-08-03 4 S 0 500 155.15 D 114424 D Stock Option (Right to Buy) 91.05 2017-08-02 4 M 0 1796 0.00 D 2026-02-01 Common Stock 1796 17960 D Stock Option (Right to Buy) 109.14 2017-08-03 4 M 0 3594 0.00 D 2025-02-02 Common Stock 3594 21563 D Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $152.50 (range $152.00 to $152.88). Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $153.93 (range $153.31 to $154.30). Open market sales reported on this line occurred at a weighted average price of $154.89 (range $154.70 to $155.40). Open market sales reported on this line occurred at a weighted average price of $156.24 (range $155.94 to $156.40). Open market sales reported on this line occurred at a weighted average price of $153.29 (range $152.63 to $153.55). Open market sales reported on this line occurred at a weighted average price of $154.21 (range $153.71 to $154.64). Open market sales reported on this line occurred at a weighted average price of $155.15 (range $154.73 to $155.53). The option vests in 16 quarterly installments from 2/2/2016. The option vests in 16 quarterly installments from 2/3/2015. /s/ Omar White, Attorney-in-Fact 2017-08-04